VETERINARY TEAM REFERENCE

DEA & state schedules

Scheduling applies to the medication, not to the patient. This independent reference is not affiliated with the DEA.

Marbofloxacin

FEDERAL STATUS

Not federally scheduled

The identified ingredients in this entry are not listed in the reviewed federal schedules. Prescription-only status, product restrictions and state law are separate questions.

Federal source ↗

State / prescribing or dispensing jurisdiction

STATE STATUS

Select a jurisdiction

Choose the state relevant to prescribing or dispensing. Patient residence alone may not determine every applicable rule.

What each federal schedule means

Highlighted rows match the verified federal or selected state schedule. The schedule describes legal control and abuse potential; it does not rank clinical usefulness or establish a dose.

Federal Schedules I–V: meaning and practice implications
Schedule	Meaning and practice
I	High abuse potential; no currently accepted medical use in U.S. treatment; lacks accepted safety under medical supervision. In practice: Not available for routine veterinary prescribing. Authorized research is a separate pathway.
II	High abuse potential; accepted medical use, sometimes with severe restrictions; abuse can cause severe dependence. In practice: No prescription refills under federal law. Strict prescribing, security and record requirements apply.
III	Less abuse potential than I or II; accepted medical use; abuse can cause moderate or low physical dependence or high psychological dependence. In practice: Federal prescriptions allow up to five authorized refills within six months. State rules may be stricter.
IV	Lower abuse potential than III; accepted medical use; limited dependence risk relative to III. In practice: The same federal five-refill / six-month prescription limit applies. Controlled-drug handling still applies.
V	Lower abuse potential than IV; accepted medical use; limited dependence risk relative to IV. In practice: Still controlled. Check authorized refills and state limits; do not automatically apply the III–IV refill rule.

What this means for the chart

For a controlled medication, confirm the prescriber’s authority for the applicable schedule, the exact formulation and quantity, authorized refills, secure handling, and required inventory / dispensing records. Check the state’s veterinary rules and any prescription monitoring program (PDMP) requirements or exemptions.

A PDMP reporting requirement does not by itself make a drug scheduled. “Not federally scheduled” does not mean over the counter, risk-free, or exempt from state law. States may use additional categories, such as Schedule VI, outside the federal I–V system.

← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Marbofloxacin

A fluoroquinolone antibacterial. Zeniquin is labeled for selected susceptible bacterial infections in dogs and cats.

Fluoroquinolone antibacterialProduct-specific clinical reference

Updated October 16, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Zeniquin treats susceptible bacterial infections, not nonspecific illness.

Key prescribing checks

The label contraindicates use in cats under twelve months and in immature dogs during specified growth periods that vary by breed size.
Avoid patients with quinolone hypersensitivity. Review central nervous system disease because quinolones can cause neurological effects.
Culture and susceptibility assessment may help guide selection and prevent unnecessary fluoroquinolone use. Treatment failure warrants re-evaluation.
Concurrent antacids or mineral-containing products may alter absorption; record supplements and nonprescription medications as part of the medication list.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Dogs and cats

FDA-approved veterinary label

Susceptible skin/soft-tissue bacterial infections

Canine urinary infections also labeled; not feline urinary infection.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Bactericidal fluoroquinolone antibacterial.

Absorption, distribution, metabolism and elimination

Fasted dogs: oral bioavailability approximately 94%; oral terminal half-life about 11 hours versus about 13 hours in studied cats.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Zeniquin

Dogs and cats; oral tablets

Contraindications · when not to use

Quinolone hypersensitivity.
Cats younger than 12 months.
Rapidly growing immature dogs: small/medium breeds through 8 months, large breeds through 12 months, giant breeds through 18 months.

Precautions & monitoring

Use cautiously with CNS disease; reproductive safety is unproven. Feline retinal adverse effects are a class concern.

Safety sources checked: October 16, 2026. Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Reduced appetite, vomiting, diarrhea and neurologic effects are reported.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

Filter labeled species

Selected product-label regimens — not a patient-specific prescription
Species & indication	Labeled regimen	Eligibility & source
Dogs and catsSusceptible skin/soft-tissue infectionsZeniquin tablets	1.25 mg/lb; may increase to 2.5 mg/lb Oral · Once daily 2–3 days beyond clinical resolution; maximum 30 days	Veterinary selection required. Verify full dosing label ↗
DogsSusceptible urinary tract infectionZeniquin tablets	1.25 mg/lb; may increase to 2.5 mg/lb Oral · Once daily At least 10 days	Reassess nonresponse. Verify full dosing label ↗

Contraindicated in cats <12 months and rapidly growing dogs within label breed-size age limits.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Zeniquin

Dogs and cats; oral tablets

Avoid concurrent oral mineral cations, antacids or sucralfate because absorption may fall.

Interaction source ↗

Monitoring

Culture when appropriate; reassess if no improvement within 5 days.

Client counseling

Avoid concurrent oral mineral cations, antacids or sucralfate; respect growth-related age restrictions.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Follow the tablet package storage directions.

Brands, formulations & ingredient identity

Active ingredients

Marbofloxacin

Zeniquin identifies marbofloxacin tablets, not enrofloxacin or another fluoroquinolone. Related class members are not ingredient synonyms.

The label specifies veterinary species and infection indications. An ingredient match does not demonstrate the same spectrum, safety profile or patient eligibility as another antibiotic.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Zeniquin

Formulation: Oral tablet
Label / product scope: Dogs · Cats

Marbofloxacin veterinary product; developmental age restrictions apply.

Product label / source ↗

References & review status

Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

01DailyMed: marbofloxacin product labeling ↗

Search another medication or supplement →

Prescribing overview

Key prescribing checks

Uses by species

Dogs and cats

Pharmacology & pharmacokinetics

Mechanism and clinical role

Absorption, distribution, metabolism and elimination

Contraindications & cautions

Contraindications · when not to use

Precautions & monitoring

Adverse effects

Dosing & administration

Drug & supplement interactions

Zeniquin

Monitoring

Client counseling

Storage & handling

Brands, formulations & ingredient identity

Active ingredients

Zeniquin

References & review status

Related Resources